UCL is today launching the UCL Technology Fund to invest £50 million in commercialising its world-leading research emerging over the next five years.
Business letters: October 20
18 October 2013
YOU say that turning university science projects into big companies is mostly impossible (“Imperial needs to pick more winners”, last week). Yet the acquisition of Spirogen by Astra Zeneca for $440m (£272m) last week shows that substantial returns to investors are possible from university research.
Read: The Sunday Times